New Drug May Ease Social Impairment of AutismResearchers have launched a pilot clinical trial of a new medication aimed at relieving the sociability problems of adolescent and young adult patients with autism spectrum disorders (ASD).

 The medication used, D-Cycloserine, originally was developed to treat tuberculosis, but previous studies showed, by chance, that it might change social behavior.

 “What makes this important is you might have someone with a 125 or 130 IQ who’s unemployable” because of their social impairments, said lead investigator Maria R. Urbano, M.D., associate professor of psychiatry and behavioral sciences at Eastern Virginia Medical School (EVMS). Their difficulties in social functioning significantly reduce quality of life for those with ASD.

 Researchers say that individuals with Autism Spectrum Disorders are either disinterested in social interactions or find them unpleasant.

 “They often don’t understand what other people are thinking or feeling and misinterpret social cues,” said Stephen I. Deutsch, M.D., Ph.D., of EVMS.

 “Sadly, persons with autism spectrum disorders are often painfully aware of their limited sociability, which can lead to profound feelings of sadness and frustration.”

 The trial will show whether the medication, which is already known to be safe for use in humans, has similar effects on the sociability deficits of persons with autism as it does in mice.

 As part of their research, EVMS scientists verified that is a valid animal model of the limited sociability seen in persons with ASD.

 EVMS scientists found that in the presence of another mouse, a specific mouse strain known as the BALB/c mouse moves as far away as possible and does not interact as normal mice do — just as people with autism often avoid making social contact with other people.

 This finding gave researchers a way to test whether D-Cycloserine can alter the function of certain receptors in the brain known to affect sociability and help the animals be more at ease around others.

 In preliminary studies at EVMS, the medication appeared to resolve the Balb/c mouse’s deficits of sociability; it behaved as a normal mouse would when placed near another.

 EVMS’ laboratory studies with the Balb/c mouse led investigators to hypothesize that D-Cycloserine could ease the impaired sociability of people with autism, such as avoiding eye contact and personal interaction. Those traits can severely limit the possibility of employment and independent living.

 The research is supported by a grant from the Hampton Roads Community Foundation.

 Source: Eastern Virginia Medical School